CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its quarter ended June 30, 2022.
“Our strong sales performance in Q2 resulted in 20% growth over the same period last year, and 10% growth over the previous quarter. Sales from Finceramica’s CustomizedBone implant contributed to this performance and we expect the sales momentum to continue into Q3. Further, we are making good progress toward improving surgeon access to our product line through additional Group Purchasing Organization contracts”, said Ross Bjella, Kelyniam’s CEO. “2022 surgical activity is returning to historical trends so the Company expects to benefit from the upward trend in surgical volume with less variability due to new Covid variant transmission and the associated effect of delayed procedures.”
The company also made significant investments in infrastructure, regulatory matters and marketing over the previous six months. These investments demonstrate the Company’s pursuit of top line growth and the infrastructure necessary to support it. The company is funding the investments out of operating income and has not taken on additional debt.
Financial highlights for the six months ended June 30, 2022 and the same period in 2021 include:
- Total revenue of $1,469,354 compared to $1,224,059 for solid growth of 20.0%
- Gross margin of $1,186,419 compared to $ 944,463
- Operating Income of $ 38,394 compared to of $47,167
The complete financials can be found here.
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and
uncertainties that may cause actual results to differ materially, including the following: changes in economic
conditions; general competitive factors; the Company’s ability to execute its service and product sales plans;
changes in the status of ability to market products; and the risks described from time to time in the Company’s
SEC reports. Contacts: Ross Bjella, Investor Relations or Terrance Kurtenbach, Chief Financial Officer
Kelyniam Inc. (800) 280 – 8192